PostEra

#NEWS: Today marks a significant milestone as we announce our new #AI collaboration with Amgen! Alongside our existing collaborations with Pfizer and the NIH, this collaboration will go such a long way in helping us advance drug discovery and bring more cures to patients.   Amidst much AI hype and a difficult market backdrop, the whole team has pushed hard over these last 4 years to prove the value of our AI platform on real discovery programs, with multiple partners, across multiple therapeutic areas. Thanks to the brilliant scientists, BD team, and Legal at Amgen who worked with us to make this happen. Press Release ➡ https://lnkd.in/e4brSWQr #machinelearning #pharma #drugdiscovery #startup #biotech #drugdevelopment

A great reading insight from Aaron Morris at PostEra. Very inspiring article touching on the transformation fundamentals of AI in drug discovery... Would be so happy to get the viewpoint on this from some of my chemistry colleagues! #LifeHubLyon #DigitalTransformation #AIinDrugDiscovery

📢 Don’t miss the 1st ACS MEDI Webinar! Join us to explore the role of Machine Learning in Drug Discovery. You’ll hear from two experts in Medicinal Chemistry, and the session will close out with a Round Table Discussion. We are pleased to introduce our first speaker, Dr. Alpha Lee from PostEra, United States. 📅 Date: September 26  ⏰ Time: 1:00-3:00 PM EST 💻 Register today to secure your spot: https://lnkd.in/enhvPXpc #DrugDiscovery #MachineLearning #MedicinalChemistry #ACSMEDIWebinar

PFIZER MED DESIGN PUBLICATION: It's often worth comparing where things started out and where things end up in the molecular evolution of a chemical series (Take a look at the graphic). In this publication, Michelle Garnsey and her team report on an orally active SARS-CoV-2 PLpro inhibitor from a machine learning–driven anti-viral drug discovery program run in collaboration with PostEra. The highlighted compound (PF-07957472, compound 4 in the paper) is extensively characterized and represents an almost 1000x improvement in biochemical potency from the starting point. I did post this when it originally hit BioRx but it looks even nicer now that it's set out as a paper in Science Advances! Well done to Michelle's Pfizer Med Design co-authors Ellene Mashalidis, Lisa Aschenbrenner, Andrew Ephron, Jeanne Chang, Kristen Ford, Tim Foley, Zsófia Lengyel-Zhand, Magdalena Korczynska, Jana Polivkova, Colin Rose, Sylvie Sakata, Huixian Wu, JINZHI(Jenny) ZHANG and Lei Zhang. Link to paper in Comments #pfecolleague

Hot off the press Science Advances paper from Pfizer and PostEra 🔥 💡 PostEra's AI approach was able to make rapid progress on a first in class target, achieving in vivo efficacy in under 8 months of chemistry. 💡 This is, to our knowledge, the first time a pharma company has independently tracked and externally published the progress of a partner's AI-driven approach on a program. What you'll notice is the teams' focus not just on leveraging PostEra's machine learning, but the criticality of a well-oiled CRO and logistics gameplan and a smooth partnership between PostEra's chemistry and Pfizer's structural biology and assay teams. Really a team effort. Take a read ➡ https://lnkd.in/gvW6aTQ2 #drugdiscovery #biotech #pharma #machinelearning

Could PostEra have all 50 states represented? Maybe one day. Right now we're planning our next company offsite. Any US locations you've enjoyed doing company gatherings at?

Our most recent onsite was the 6th PostEra has done as a company. We've been remote-first since inception (and continue to benefit from the oft cited advantages it offers), but we introduced onsites to help manage some of the interpersonal loss that is the price of remote work. A couple of key learnings we've found over the past 2 years: - IRL People like IRL People: Blatantly obvious, but it's much easier to build meaningful rapport and friendship with colleagues when you're in-person. The serendipity of 'water cooler' conversation helps not only with forming connections, but also passing around ideas between team members that may get trapped in the zoom silos of remote work. - Sprints haven't really worked: We’ve struggled to get real long term value from these, quite contrary to expectations. Sprints around new, blue sky ideas usually end up with cool MVP solutions but momentum usually doesn’t translate once ordinary remote life continues. Any pre-existing tasks that we sprint on can get done fine but not meaningfully better than the remote setting they originated in. - Protect leaders from meetings: In person can be a great time for strategic planning and retrospectives, but team members don’t want their managers constantly being pulled into meetings by the founders, especially when the manager is trying to build meaningful culture and rapport within their own team. As such we have a leadership day appended to our onsites where all the planning and reviews can be dealt with before the broader company arrives. We fill onsite agendas only with things that can be achieved much better in person, and over time these onsites have become a core rhythm of the company that the team frequently notes as highlights of the PostEra year.

3 has turned into 33! Fantastic to welcome the whole PostEra team from across 13 US states, and we've finally got Boston weather that lets us get out the office. #boston #onsite #startup #drugdiscovery #biotech #pharma #ai

“As medicinal chemists and drug hunters, we have an opportunity to make significant and positive change. It is critical that we educate ourselves and others — that we research and support women’s healthcare.” In honor of International Day of Action for Women's Health, GV advisor Wendy Young calls for the prioritization of women’s health research in ACS Publications' Journal of Medicinal Chemistry. Learn more — https://bit.ly/4byMSKT

Today we're excited to provide a quick update on the progress of our latest collaboration with Pfizer, the AI Lab.   Update ➡ https://lnkd.in/gyTtDR5j   Over the last 4 years we've partnered with Pfizer to advance the field of AI for medicinal chemistry and are now using these advances to accelerate numerous drug discovery programs. Take a read of the rapid progress made on one of these programs.   Recent BioRxiv Publication ➡ https://lnkd.in/eRvvyUMe A huge thanks to all the Pfizer and PostEra teams who've worked hand-in-hand to move fast, leverage new technology, and help make progress like this possible.